



Trojan Income Fund

All data as at 30 June 2021

The investment objective of the Trojan Income Fund is to seek to achieve income with the potential for capital growth in the medium term (3 to 5 years). The Fund must invest at least 80% of its assets in UK equities.

Prices 350.13p

'O' accumulation shares

'O' income shares **Fund Size**


179.73p

Historic Dividend Yield 2.7%


£2.735m

'O' income shares

Percentage Growth from 30/09/2004 to 30/06/2021



Asset Allocation



Source: Factset, Asset Allocation subject to change

Total Return to 30 June 2021	30/09/04 Since launch	30/06/11 10 years	30/06/16 5 years		30/06/20 1 year	31/12/20 6 months
Trojan Income Fund O Acc	+250.1%	+106.0%	+20.1%	+6.4%	+8.2%	+5.8%
IA UK Equity Income (TR)	+214.6%	+94.9%	+33.7%	+5.5%	+25.5%	+12.2%
FTSE All-Share Index (TR)+	+219.2%	+85.5%	+36.9%	+6.3%	+21.5%	+11.1%

Discrete Calendar Annual Returns	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021 YTD
Trojan Income Fund O Acc	+11.7%	+16.8%	+5.0%	-12.1%	+14.7%	+14.4%	+6.3%	+9.9%	+20.2%	+10.0%	+10.7%	+10.2%	+6.3%	-7.1%	+20.4%	-9.6%	+5.8%

^{* ©} FTSE International Limited 2021

Source: Lipper

June Commentary

Your Fund delivered a return of +1.6% during the month of June compared to +0.2% for the FTSE All-Share Index (TR). This positive monthly return continues the trend of improved performance since the end of February, which marked the point when a four-month period of sharp sector rotation began to reverse again. As we have often said in the past, such extreme changes of market sentiment can have a significant impact on short-term relative performance. Our firm belief is that over the longer term your Fund will deliver competitive returns despite occasional setbacks such as this.


Individual companies that performed well in the month included the two major pharmaceutical companies, AstraZeneca and GlaxoSmithKline, as well as Croda (the speciality chemicals company) and RELX (the global information and analytics provider). Since the end of February, your Fund has produced double-digit returns, in excess of the market. This reflects the fact that many high-quality companies have bounced back from excessively depressed valuations.

A new holding in Admiral Group has been initiated. This specialist motor insurance company has a 21% share of the UK market and still has plenty of scope to grow in the UK as well as in Europe. The business generates a market-leading return on equity and regularly produces more cash than it needs, resulting in a comfortably affordable ordinary dividend that is

supplemented payouts. We believe that this is a highquality UK franchise capable of sustaining attractive value creation and enhancing the Fund's future dividend growth.

As the global economy moves into a postpandemic phase, led by more fully vaccinated nations such as the UK, the longer-term impact of the virus, both human and economic, will become apparent. The inflationary consequences will be critical. The coming months will determine whether the sharp rises in the price of some commodities and products are being caused by temporary bottlenecks or something more permanent that can challenge the disinflationary trends that have prevailed over recent years.

Past performance is not a guide to future performance.



Source: Lipper

Risk analysis since launch (30/09/04)	Fund	IA ²	Index+
Max Drawdown ¹	-28.1%	-44.9%	-45.6%
Annualised Volatility ³	+9.9%	+13.4%	+13.5%

 $^{^{1}}$ Measures the worst investment period 2 IA UK Equity Income (TR) * FTSE All-Share Index (TR) 3 Measured by standard deviation of annual returns Source: Lipper

Top 10 holdings % Fund 6.4 Diageo Reckitt Benckiser 5.3 Unilever 5.2 Experian 5.2 RELX 4.9 Paychex 3.8 Croda International 3.7 Nestlé 3.4 GlaxoSmithKline 3.3 AstraZeneca 3.3 Total Top 10 44.7 29 other holdings 52.6 Cash & Equivalent 2.7 TOTAL 100.0

Source: Factset. Holdings subject to change

Fund Ratings





Silver

Dividend Track Record Since 31 January 2005 Full year to 31 January

Source: Troy Asset Management Limited

Past Performance Is Not A Guide To Future Performance

Fund information

A copy of the latest Prospectus and the KIID for each class (in English) upon which you should base your investment decision is available from Link Fund Solutions Ltd, the Fund's Authorised Corporate Director and Link Fund Administrators Ltd (Authorised and Regulated by the Financial Conduct Authority) on 0345 608 0950. The Trojan Income Fund is closed to new direct investments, but is still available to new investors through major fund platforms.

tructure

Sub-fund of Trojan Investment Funds

UK UCITS

Investment Manager

Troy Asset Management Limited

33 Davies Street London W1K 4BP

Tel: 020 7499 4030 Fax: 020 7491 2445

email: busdev@taml.co.uk

Co-managers

Francis Brooke Blake Hutchins

Hugo Ure

Currency £ Sterling

Launch Date 30 September 2004

Net Yield (historic 'O' Inc shares)

Ongoing Charges

'O' (ordinary) shares: 1.01%
'S' (charity) shares: 0.76%

Dividend Ex Dates

1 August (interim), 1 February (final)

Dividend Pay Dates

30 September (interim), 31 March (final)

Authorised Corporate Director

Link Fund Solutions Limited

Tel: 0345 300 2110

ISINs

2.65%

GB00B01BNW49 (O Inc), GB00B01BP176 (O Acc) GB00B05M9W55 (S Inc), GB00B05M9V49 (S Acc)

Benchmarks

For more information on the benchmarks used please refer to the 'use of benchmarks' section in the fund information sheet, available from our <u>website</u>

Dealing

Daily at noon

Tel: 0345 608 0950

Registrar

Link Fund Administrators Limited

Auditor

Ernst & Young LLP

Depositary

The Bank of New York Mellon (International) Limited

Bloomberg

TROJINC_LN (O Acc), TROJINI_LN (O Inc)

SEDOL

B01BP17 (O Acc), B01BNW4 (O Inc)

Pricing

"O" share class prices published daily in the FT

Important Information

smaller cap companies are higher risk than investments in larger companies. The value of an investment and any income from it may fall as well as rise and investors may get back less than they invested Neither the views nor the information contained within this document and the latest report and accounts. The investment policy and process of the fund(s) may not be suitable for all investors. If you are in any doubt about whether the fund(s) is/are suitable for you, please contact a professional advisor. References to specific securities are included for the purposes of illustration only and should not be contact as recommendation to buy or self these securities. Derivatives (whose value is linked to that of another investment, e.g. company shares, currencies) may be used to manage the risk profile of the fund. Although Troy Asset Management Limited considers the information included in this document to be reliable, no warranty is given as to its accuracy or completeness. The opinions expressed are expressed at the date of this document and, whilst the opinions stated are honestly held, they are not guarantees and should not be relied upon and may be subject to change without notice. Third party data is provided without warranty or liability and may belong to a third party. The fund(s) is/are registered for distribution to the public in the UK-but not in any other jurisdiction. The distribution of shares of subfunds of Trojan Investment Fund ("Shares") in Switzerland, the instrument of incorporation documents ("Shares") in Switzerland in Section 305 ("Shares") in Switzerland, the instrument of incorporation documents ("Shares") in Switzerland in Section 305 ("Shares") in Switzerland in Sect